PureTech Health plc (PRTC)
Market Cap | 505.61M |
Revenue (ttm) | 15.62M |
Net Income (ttm) | -50.35M |
Shares Out | 27.28M |
EPS (ttm) | -1.80 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 546 |
Open | 18.12 |
Previous Close | 18.38 |
Day's Range | 17.08 - 18.12 |
52-Week Range | 17.08 - 38.51 |
Beta | 0.84 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 29, 2023 |
About PRTC
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed... [Read more]
Financial Performance
In 2022, PRTC's revenue was $15.62 million, a decrease of -10.18% compared to the previous year's $17.39 million. Losses were -$50.35 million, -16.85% less than in 2021.
Financial StatementsNews

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics...

PureTech Health plc – Half-Year Report
BOSTON--(BUSINESS WIRE)--PureTech Health plc – Half-Year Report.

PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.

PureTech Announces Annual Results for Year Ended December 31, 2022
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2022.

PureTech Health: Notice of Results
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Friday, April 28, 2023, at 2:00 AM EDT/...

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
Royalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds.

PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health, a hea...

PureTech to Present at the SVB Securities Global Biopharma Conference
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

Vedanta Biosciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced ...

PureTech Provides End of Year Report on Key Progress
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

PureTech's LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health, a h...

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech's Glyph™ Platform
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

PureTech to Present at Two Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devast...

PureTech to Present at the Jefferies London Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastat...

Vedanta Biosciences to Present at the 9th International Human Microbiome Consortium Congress
CAMBRIDGE, Mass.

PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference

Form 8 (OPD) PureTech Health PLC
OPENING DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

PureTech to Present at the Morgan Stanley Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Morgan Stanley Global Healthcare Conference

PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022
BOSTON--(BUSINESS WIRE)--PureTech Presents Data for LYT-100 Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at ERS International Congress 2022

PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye Pharmaceuticals
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye Pharmaceuticals

PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, In...

PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results